From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers.

@article{Braido2012FromT,
  title={From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers.},
  author={Fulvio Braido and Stephen Holgate and Giorgio Walter Canonica},
  journal={Pulmonary pharmacology & therapeutics},
  year={2012},
  volume={25 6},
  pages={483-6}
}
Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new generation of products, mostly biotech, aimed at modifying a specific pathogenetic mechanism. In other word we are moving fast to targeted therapy, which represents the first step toward personalized… CONTINUE READING